API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 5 sources · 3 days · First seen · Last updated

Sjögren disease research and drug development

Overview

Recent clinical developments regarding Sjögren disease, a chronic autoimmune disorder, have focused on both long-term patient risks and new therapeutic options.

Research presented at the American College of Rheumatology annual meeting included a twenty-five year analysis of United States decedents from 1999 through 2024. This study identified disparities in cardiovascular mortality, suggesting that chronic inflammation and metabolic factors increase vascular risks for those with the syndrome.

In terms of pharmaceutical progress, several investigational treatments have shown promise. Novartis reported positive long-term data for ianalumab, a monoclonal antibody targeting B-cells, with continued improvements in disease activity through week 108. Additionally, a multicenter trial evaluated the efficacy of the Janus kinase inhibitor baricitinib.

Furthering these developments, Amgen announced positive results from its Phase 3 OASIZ-301 trial for dazodalibep, an experimental CD40L antagonist. The randomized, placebo-controlled study, which targeted moderate to severe Sjögren’s disease, met its primary endpoints after 48 weeks. The 1,500 mg dose, administered every four weeks, reduced systemic disease activity by an average of 5.6 points compared to 3.8 points for the placebo group, while also significantly improving patient-reported dryness symptoms. The 3,000 mg regimen, administered every twelve weeks, showed a 5.2-point reduction in disease activity. Amgen reported that benefits were observable as early as week four and were maintained through week 48. The company intends to present full data at the ACR Convergence 2026 meeting.

Entities

American College of Rheumatology · Food and Drug Administration · ACR Convergence 2026 · Novartis · Amgen

Timeline

  1. [BUSINESS] 3 sources
    Amgen reports positive Phase 3 trial results for Sjögren’s drug

    Amgen’s Phase 3 trial for dazodalibep met primary endpoints, showing significant reduction in Sjögren’s syndrome disease activity and improved dryness symptoms over 48 weeks.

  2. [HEALTH] 2 sources
    Sjögren disease research highlights cardiovascular risks and new drug efficacy

    Research presented at the American College of Rheumatology meeting highlights increased cardiovascular mortality risks in Sjögren disease and shows long-term efficacy for the investigational drug ianalumab.

Sources

ad-hoc-news.de · blockonomi.com · cryptocompass.com · emjreviews.com · world-today-journal.com

This summary has been updated 1 time: see revision history